AstraZeneca Pharma receives approval for Dapagliflozin from DCGI
AstraZeneca Pharma India Limited has received Permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from the Drugs Controller General of India for Dapagliflozin Tablets 10 mg.
Dapagliflozin Tablets 10mg is indicated for the treatment of heart failure in adults. Forxiga (dapagliflozin) was developed by Bristol-Myers Squibb and AstraZeneca. It belongs to a class of drugs known as SGLT2 (sodium-glucose cotransporter 2) inhibitors.